Searchable abstracts of presentations at key conferences in endocrinology

ea0016p288 | Endocrine tumours | ECE2008

Effects of the potent deacetylase inhibitor Panobinostat (LBH589) against poorly differentiated and anaplastic thyroid cancer cells

Catalano Maria Graziella , Pugliese Mariateresa , Bosco Ornella , Fortunati Nicoletta , Boccuzzi Giuseppe

Poorly differentiated and anaplastic thyroid carcinomas are aggressive human cancers that are resistant to conventional therapy. DAC inhibitors (DACi) are a promising class of drugs, acting as anti-proliferative agents by inducing apoptosis and cell cycle arrest.Panobinostat (LBH589) is a potent DACi belonging to a structurally novel cinnamic hydroxamic acid class of compounds, able to inhibit the activity of different isoforms of HDACs (HDAC 1, 3–6...

ea0022p767 | Thyroid | ECE2010

Panobinostat restores iodine uptake in primary cultures of undifferentiated thyroid tumours

Catalano Maria Graziella , Pugliese Mariateresa , Germano Antonina , Poli Roberta , Palestini Nicola , Mainini Franco , Fortunati Nicoletta , Boccuzzi Giuseppe

A functional sodium iodide symporter (NIS) is essential for radioiodine treatment of thyroid cancer. Unfortunately, most of de-differentiated tumours as well as anaplastic thyroid cancers loss the ability to concentrate iodine. Loss of NIS expression usually depends on epigenetic modifications, suggesting the use of epigenetic drugs as promising tools for re-differentiation. Panobinostat (LBH589) is a novel deacetylase inhibitor, acting at nanomolar concentrations, currently i...